Evidence map›Paper›PMID 28634723›Full record

Trial reportJournal of gastroenterology2018

Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.

Akihiro Matsumoto, Shuhei Nishiguchi, Hirayuki Enomoto, Jong-Hon Kang, Yasuhito Tanaka, Noboru Shinkai, Masayuki Kurosaki, Masaru Enomoto, Tatsuo Kanda, Osamu Yokosuka and 18 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Update on the management and treatment of viral hepatitis.World journal of gastroenterology · 2021
    Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Akihiro MatsumotoDepartment of Medicine, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto, 390-8621, Japan.
Shuhei NishiguchiDivision of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Hirayuki EnomotoDivision of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Jong-Hon KangCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Yasuhito TanakaDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Noboru ShinkaiDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Masayuki KurosakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Masaru EnomotoDepartment of Hepatology, Osaka City University Medical School, Osaka, Japan.
Tatsuo KandaDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Osamu YokosukaDepartment of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroshi YatsuhashiThe Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Shinya NagaokaThe Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Chiaki OkuseDivision of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Tatehiro KagawaDivision of Gastroenterology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Tetsuya MineDivision of Gastroenterology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Koichi TakaguchiDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Satoru SaitoDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.
Keisuke HinoDepartment of Hepatology and Pancreatology, Kawasaki Medical School, Kurashiki, Japan.
Fusao IkedaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Shotaro SakisakaDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Daisuke MoriharaDepartment of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Shiho MiyaseDepartment of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital, Kumamoto, Japan.
Masataka TsugeDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kazuaki ChayamaDepartment of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Naoki HiramatsuDepartment of Gastroenterology, Osaka Rosai Hospital, Sakai, Japan.
Yoshiyuki SuzukiDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Kazumoto MurataThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.
Eiji TanakaDepartment of Medicine, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto, 390-8621, Japan. etanaka@shinshu-u.ac.jp.ORCID http://orcid.org/0000-0002-0724-2104

Funding

Japan Agency for Medical Research and Development (AMED) Research Program on Hepatitis and the Program for Basic and Clinical Research on HepatitisMinistry of Health, Labor, and Welfare of Japan Research Program on Hepatitis and the Program for Basic and Clinical Research on Hepatitis
6 · The paper itself

Abstract

backgroundThis prospective cohort study searched for factors associated with a response to nucleos(t)ide analogue/peg-interferon (NUC/peg-IFN) sequential therapy.

methodsA total of 95 patients with chronic hepatitis B being treated with NUCs were enrolled. Immediately following NUC cessation, peg-IFN was administered at 180 µg/dose weekly for 48 weeks.

resultsTwenty-six patients (27%) were judged to be responders at 48 weeks after the completion of peg-IFN. Analysis of baseline factors revealed that hepatitis B surface antigen (HBsAg) <3.1 log IU/ml and HB core-related antigen (HBcrAg) <3.9 log U/ml were significant indicators of a treatment response. The levels of the markers decreased in both responders and non-responders during peg-IFN therapy but continued falling in responders only after halting peg-IFN. Lower HBsAg (<2.0 log IU/ml) and HBcrAg (<3.8 log U/ml) levels at the time of response judgment were also significantly associated with a favorable response. While lower HBcrAg at baseline was the sole predictor of decreased HBcrAg levels at judgment, lower HBsAg, lower HBcrAg, and the use of adefovir dipivoxil at baseline predicted decreased HBsAg levels at the study endpoint. The use of adefovir dipivoxil was also associated with higher serum IFN-λ3, which might have contributed to the reduction in patient HBsAg levels.

conclusionsThe combinational use of HBsAg and HBcrAg levels at baseline and their changes throughout sequential therapy may be useful for predicting a response to NUC/peg-IFN sequential therapy.

Indexed as

AdenineAdultAgedAged, 80 and overAntiviral AgentsBiomarkersDrug Administration ScheduleDrug MonitoringDrug Therapy, CombinationFemaleHepatitis B, ChronicHepatitis B Core AntigensHepatitis B Surface AntigensHumansInterferon-alphaMaleadefovir dipivoxilAdenineAntiviral AgentsBiomarkersHepatitis B Core AntigensHepatitis B Surface AntigensInterferon-alphaOrganophosphonatespeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsAnti-viral therapyChronic hepatitisCovalently closed circular DNAHepatitis B core-related antigenHepatitis B surface antigen

Identifiers

PMID28634723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.